CNSP - CNS Pharmaceuticals, Inc.
| Previous Close | 4.0300 |
| Open | 4.0300 |
| Bid | 3.8000 x 900 |
| Ask | 4.0000 x 3100 |
| Day's Range | 3.9000 - 4.0300 |
| 52 Week Range | 3.6500 - 5.6900 |
| Volume | 47,427 |
| Avg. Volume | 166,195 |
| Market Cap | 63M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6350 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- PR Newswire
CNS' Berubicin Awarded $5.8 Million Non-Dilutive Grant from EU/Polish National Center Through its Development Partner
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, announced that its partner, WPD Pharmaceuticals ("WPD"), a Polish corporation founded by Dr. Waldemar Priebe, the founder of the Company, was awarded a $5,798,875 grant from the EU/Polish National Center for Research and Development under the Smart Growth Operational Program 2014-2020 (the "EU Grant").
- PR Newswire
CNS Pharmaceuticals Received Positive FDA Pre-IND Guidance for Berubicin
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, received positive feedback from the U.S. Food and Drug Administration (FDA) for its Pre-IND (Investigational New Drug) meeting proposal to use a lyophilized drug product, Berubicin, in Phase II clinical trials.
- PR Newswire
CNS Pharmaceuticals to Participate in the 8th Annual ROTH Deer Valley Corporate Access Event
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, and Chris Downs, Chief Financial Officer, will be attending the 8th Annual ROTH Deer Valley Corporate Access Event at the Montage Deer Valley Hotel in Park City, Utah.
- PR Newswire
CNS Pharmaceuticals Announces Full Exercise of Over-Allotment Option
HOUSTON, Nov. 21, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced the closing of the issuance of an additional 318,750 shares of its common stock pursuant to the exercise in full of the underwriters' over-allotment option in connection with its initial public offering (the "IPO"). The gross proceeds from the sale of the additional shares, before deducting underwriting discounts and commissions, was $1.3 million, bringing the total gross proceeds from the IPO to $9.8 million.
- PR Newswire
CNS Pharmaceuticals Filed Request with FDA for Pre-IND Meeting for Berubicin
HOUSTON, Nov. 21, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, filed a Pre-IND meeting request for Berubicin for IV for the Treatment of Glioblastoma Multiforme to the US Food and Drug Administration Division of Oncology Products 2, Center for Drug Evaluation and Research. In its request, the Company outlined its rationale for the continued investigation of the compound and detailed key questions for the FDA, including its permission to utilize the supply of Berubicin acquired from Reata Pharmaceuticals Inc. in the planned upcoming Phase II clinical trial.
- PR Newswire
CNS Pharmaceuticals Announces Attendance at the 24th Annual Meeting of the Society of Neuro-Oncology
HOUSTON , Nov. 20, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today ...
- PR Newswire
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
HOUSTON, Nov. 19, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, completed an agreement with Houston Pharmaceuticals, Inc. ("HPI") to obtain the rights to a worldwide, exclusive royalty-bearing, license for the chemical compound commonly known as Berubicin. CNS' licensing agreement with HPI grants the Company the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer globally. In its agreement with HPI, the Company acquired multiple U.S. patents for Berubicin.
- PR Newswire
CNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock
HOUSTON, Nov. 13, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, today announced the closing of its initial public offering of 2,125,000 shares of common stock at an initial public offering price of $4.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $8.5 million.